Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The classification of diabetes mellitus and the tests used for its diagnosis were
brought into order by the National Diabetes Data Group of the USA and the second World
Health Organization Expert Committee on Diabetes Mellitus in 1979 and 1980. Apart
from minor modifications by WHO in 1985, little has been changed since that time.
There is however considerable new knowledge regarding the aetiology of different forms
of diabetes as well as more information on the predictive value of different blood
glucose values for the complications of diabetes. A WHO Consultation has therefore
taken place in parallel with a report by an American Diabetes Association Expert Committee
to re-examine diagnostic criteria and classification. The present document includes
the conclusions of the former and is intended for wide distribution and discussion
before final proposals are submitted to WHO for approval. The main changes proposed
are as follows. The diagnostic fasting plasma (blood) glucose value has been lowered
to > or =7.0 mmol l(-1) (6.1 mmol l(-1)). Impaired Glucose Tolerance (IGT) is changed
to allow for the new fasting level. A new category of Impaired Fasting Glycaemia (IFG)
is proposed to encompass values which are above normal but below the diagnostic cut-off
for diabetes (plasma > or =6.1 to <7.0 mmol l(-1); whole blood > or =5.6 to <6.1 mmol
l(-1)). Gestational Diabetes Mellitus (GDM) now includes gestational impaired glucose
tolerance as well as the previous GDM. The classification defines both process and
stage of the disease. The processes include Type 1, autoimmune and non-autoimmune,
with beta-cell destruction; Type 2 with varying degrees of insulin resistance and
insulin hyposecretion; Gestational Diabetes Mellitus; and Other Types where the cause
is known (e.g. MODY, endocrinopathies). It is anticipated that this group will expand
as causes of Type 2 become known. Stages range from normoglycaemia to insulin required
for survival. It is hoped that the new classification will allow better classification
of individuals and lead to fewer therapeutic misjudgements.